BioLife Solutions (NASDAQ:BLFS) Shares Gap Down to $23.31
BioLife Solutions (NASDAQ:BLFS) Shares Gap Down to $23.31
BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) shares gapped down prior to trading on Tuesday . The stock had previously closed at $23.31, but opened at $22.73. BioLife Solutions shares last traded at $22.83, with a volume of 194 shares traded.
生物生命解决方案公司(纳斯达克代码：BLFS-GET Rating)的股价在周二交易前大幅下跌。该股此前收盘报23.31美元，开盘报22.73美元。BioLife Solutions的股票尾盘报22.83美元，成交量为194股。
Analyst Ratings Changes
分析师评级发生变化
A number of equities research analysts have recently issued reports on the company. B. Riley cut their target price on BioLife Solutions from $48.00 to $34.00 in a research report on Tuesday, May 17th. Cowen cut their target price on BioLife Solutions to $29.00 in a research report on Monday, August 15th. Maxim Group dropped their price target on BioLife Solutions from $60.00 to $30.00 in a research report on Thursday, May 12th. Finally, Cowen dropped their price target on BioLife Solutions from $50.00 to $32.00 in a research report on Tuesday, May 10th. One analyst has rated the stock with a sell rating and three have issued a buy rating to the stock. According to MarketBeat.com, BioLife Solutions has an average rating of "Moderate Buy" and a consensus target price of $31.25.
一些股票研究分析师最近发布了关于该公司的报告。B.莱利在5月17日星期二的一份研究报告中将BioLife Solutions的目标价从48.00美元下调至34.00美元。考恩在8月15日星期一的一份研究报告中将BioLife Solutions的目标价下调至29.00美元。Maxim Group在5月12日星期四的一份研究报告中将BioLife Solutions的目标价从60.00美元下调至30.00美元。最后，考恩在5月10日星期二的一份研究报告中将BioLife Solutions的目标价从50.00美元下调至32.00美元。一名分析师对该股的评级为卖出，三名分析师对该股的评级为买入。根据MarketBeat.com的数据，BioLife Solutions的平均评级为“适度买入”，共识目标价为31.25美元。
BioLife Solutions Trading Up 1.9 %
BioLife Solutions股价上涨1.9%
The company has a current ratio of 3.55, a quick ratio of 2.54 and a debt-to-equity ratio of 0.02. The firm has a 50-day moving average of $19.48 and a two-hundred day moving average of $18.35.
该公司的流动比率为3.55，速动比率为2.54，债务权益比率为0.02。该公司的50日移动均线切入位为19.48美元，200日移动均线切入位为18.35美元。
Insider Buying and Selling at BioLife Solutions
BioLife Solutions的内部交易和销售
Institutional Trading of BioLife Solutions
生物生命解决方案的制度性交易
Several large investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in shares of BioLife Solutions by 1.6% during the 1st quarter. BlackRock Inc. now owns 3,712,680 shares of the medical equipment provider's stock worth $84,390,000 after acquiring an additional 57,623 shares in the last quarter. Vanguard Group Inc. boosted its stake in BioLife Solutions by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 2,201,602 shares of the medical equipment provider's stock valued at $50,043,000 after purchasing an additional 54,344 shares during the period. Millennium Management LLC boosted its stake in BioLife Solutions by 45.3% during the 2nd quarter. Millennium Management LLC now owns 1,560,137 shares of the medical equipment provider's stock valued at $21,545,000 after purchasing an additional 486,631 shares during the period. Marshall Wace LLP boosted its stake in BioLife Solutions by 4.2% during the 4th quarter. Marshall Wace LLP now owns 1,346,746 shares of the medical equipment provider's stock valued at $50,193,000 after purchasing an additional 54,502 shares during the period. Finally, State Street Corp boosted its stake in BioLife Solutions by 26.1% during the 2nd quarter. State Street Corp now owns 1,270,364 shares of the medical equipment provider's stock valued at $17,544,000 after purchasing an additional 263,021 shares during the period. Institutional investors own 86.69% of the company's stock.
几家大型投资者最近改变了他们在该股的头寸。贝莱德股份有限公司在第一季度增持了BioLife Solutions的股份1.6%。贝莱德股份有限公司在上个季度增持了57,623股后，目前持有这家医疗设备供应商3,712,680股股票，价值84,390,000美元。先锋集团(Vanguard Group Inc.)在第一季度增持了BioLife Solutions 2.5%的股份。先锋集团目前持有这家医疗设备供应商2,201,602股股票，价值50,043,000美元，在此期间又购买了54,344股。千禧管理有限责任公司在第二季度将其在BioLife Solutions的股份增加了45.3%。Millennium Management LLC现在拥有这家医疗设备提供商的1,560,137股票，价值21,545,000美元，在此期间又购买了486,631股票。马歇尔·华斯有限责任公司在第四季度将其在BioLife Solutions的持股增加了4.2%。马歇尔·华斯有限责任公司在此期间额外购买了54,502股，现在拥有这家医疗设备提供商1,346,746股股票，价值50,193,000美元。最后，道富集团在第二季度将其在BioLife Solutions的持股增加了26.1%。道富集团目前持有这家医疗设备提供商1,270,364股股票，价值17,544,000美元，在此期间又购买了263,021股。机构投资者持有该公司86.69%的股票。
BioLife Solutions Company Profile
BioLife Solutions公司简介
(Get Rating)
(获取评级)
BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
BioLife Solutions，Inc.为美国、加拿大、欧洲、中东、非洲和国际上的细胞和基因治疗行业开发、制造和提供生物生产工具和服务。该公司的产品用于基础和应用研究，以及基于生物的疗法的商业制造。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on BioLife Solutions (BLFS)
- Broadcom Bounces From Institutional Bottom
- Affirm is the Underdog Starring in a Spaghetti Western
- Is Autozone A Buy Before Earnings Are Released?
- Is There Value in Verizon Shares at These Levels?
- MarketBeat Podcast: Stock Market, Bad News is Good News
- 免费获取StockNews.com关于BioLife解决方案的研究报告(BLFS)
- 博通从机构底部反弹
- 阿奎姆是意大利西部片中的失败者
- AutoZone是在收益发布之前买入的吗？
- 在这些水平上，Verizon的股价有价值吗？
- 市场Beat播客：股市，坏消息就是好消息
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
每日收到有关BioLife解决方案的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对BioLife Solutions和相关公司的最新新闻和分析师评级的每日简要摘要。